Retatrutide vs Adamax
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Adamax
Adamax is a modified version of Semax with an adamantane group attached, designed to enhance its nootropic effects and extend duration of action compared to standard Semax.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Adamax |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Similar to Semax - enhances BDNF expression and modulates dopamine/serotonin systems. The adamantane modification may increase lipophilicity and CNS penetration. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Intranasal: 100-500mcg 1-2 times daily. Lower doses than standard Semax may be effective due to enhanced potency. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Intranasal spray is most common route. More stable than standard Semax. Often used for acute cognitive enhancement. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Similar to Semax - possible irritability, hair shedding, or overstimulation. May have stronger effects than standard Semax. |
| Best For |